Please use this identifier to cite or link to this item: https://repository.iimb.ac.in/handle/2074/16616
DC FieldValueLanguage
dc.contributor.authorKumar, Ashutosh
dc.date.accessioned2021-01-20T12:31:03Z-
dc.date.available2021-01-20T12:31:03Z-
dc.date.issued2010
dc.identifier.urihttps://repository.iimb.ac.in/handle/2074/16616-
dc.description.abstractAugmentin is one of the best anti-biotic available in the market and is GSK's brand for Coamoxiclav. Augmentin was the research molecule of smikthline beachem and was patented in 1983 by them but it became a generic molecule after the patent expired and today there are more than 300 odd competitors exist in the market including all Indian players such as Dr. Reddy's Lab. Cipla. Ranbaxy etc. The project was to understand the current prescription pattern of doctors and to indentify target doctors and indications, also to identify potential competitors among advanced anti-biotic markets. Based on the observations, we have to devise the future marketing strategies for the product going forward . Augmentin was found to be first line of treatment for Acute Otitis Media and Lower Respiratory Tract Infections. Its usage was in almost in all the departments as an advanced antibiotic and for some of the doctors it was silver bullet. When analyzed the value chain, we found a lot of discounting given to stocktists and retailers in case of competitor products and a lot of push marketing going on. Through conjoint analysis. price came out to be the least important utility across all the cities and all specialties. Bacterial and Clinical Efficacy topped the utility in all scenarios with brand and quality following after. Current ongoing price war in the co-amoxiclav market came out as few doctors specifically pointed out. Differential prescription is very common among pediatricians compared to ENT and Consultant Physicians. The marketing team needs to penetrate in to newer areas like Dermatology and Dentistry. They should market more aggressively in the areas diabetology and gynecologist. Quality being the main USP of GSK products, the representatives need to carry more input related to quality aspect of Augmentin.
dc.publisherIndian Institute of Management Bangalore
dc.relation.ispartofseriesPGP_SP_P10_014
dc.subjectHealth care industry
dc.subjectAnti-biotic market
dc.subjectMarketing strategy
dc.subjectPharmaceutical industry
dc.titleUnderstanding doctors' perception about augmentin in advanced Anti-biotic market and devising future marketing strategy
dc.typeSummer Project Report-PGP
dc.pages10p.
dc.identifier.accessionE34934
Appears in Collections:2010
Files in This Item:
File SizeFormat 
PGP_SP_P10_014.pdf764.33 kBAdobe PDFView/Open    Request a copy
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.